Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCI Annual Report 2015

May 15, 2015

52383_rns_2015-05-15_f5dc0fca-878d-4d3c-992b-3879bcf59394.pdf

Annual Report

Open in viewer

Opens in your device viewer

員工數Employee:213 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣697佰萬元(NTD 697mn) 營業項目Business: 原料藥API(55.06%) 中間體Intermediate(37.67%) 特用化學品 Custom-made chemicals(7.27%)

公司概況Outline

Y2014 Y2015

洲Europe
42.65% 38.78%

洲America
21.70% 25.07%

洲Asia
18.18% 21.24%

內Taiwan
16.63% 9.46%
他 others
0.84% 5.45%
計Total
100.00% 100.00%

Unit: K NTD

2014 2015 to date
營收Sales 1,491,862 443,065
營業成本COGS (1,012,509) (273,443)
毛利Gross Profit 479,353 169,622
毛利率 GP Ratio 32.1% 38.3%
營業費用Operating Expenses (183,987) (53,885)
營業利益Operating Income 295,366 115,737
營業外損益Non-Operating In/Ex 39,728 (2,070)
稅前淨利 Net Profit before Tax 335,094 113,667
所得稅Income Tax (70,255) (20,849)
本期淨利Net Profit after Tax 264,839 92,818

產品組合-Products

Y2012 % Y2013 % Y2014 %
V.A. 18.66% PGA 18.31% PGA 17.49%
PGA 16.61% Di-VaNa 16.92% Di-VANa 10.09%
Di-VaNa 15.97% S20/38 8.39% LPF.Na 8.74%
PPON 7.88% V.A. 8.23% S20/38 8.25%
Pent-2 4.78% LPF.Na 6.58% V.A. 8.15%
5-HMT 4.33% PPON 6.53% DBS 4.60%
M85 3.89% 5-HMT 4.51% 5-HMT 4.12%
DBS 2.73% PEB.Na 3.98% NaVA 3.65%
M115 2.59% NaVa 3.34% Pent-2 3.64%
M74 2.18% DBS 2.63% T115 3.33%
Total 79.62% Total 79.42% Total 72.06%
No. Product % 2015 Sales (NT\$)
1 HOCLQ Sulfate 17.86% 111,607,197
2 PGA 14.97% 93,554,618
3 LPF.Na 13.29% 83,015,044
4 V.A. 9.07% 56,643,217
5 Di-VANa 8.68% 54,223,784
6 DBS 5.46% 34,113,986
7 Pent-2 4.33% 27,047,292
8 S-MMAA 3.49% 21,815,500
9 T-115 3.22% 20,143,000
10 3-Azetidinol.HCl 2.06% 12,899,411

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2015 sales: 94M

2個客戶 2 customers

產品介紹Product

Divalproex Sodium (Di-Va)

學名藥於2009推出 Generic came out in 2009 10個客戶 10 customers 2015 sales: 54M

Anti-inflammatory (Loxoprofen sodium)

日本市場200-300公噸 Japan market:200-300MT 2015 sales: 83M

S20/38

臨床藥物 Medication in clinical trial

Valproic Acid (VA)

20個客戶 20 customers 2015 sales: 57M

Sodium Valproate (NaVA)

24 客戶 24 customers 2015 sales: 12M

5-HMT – Ritonavir,Lopinavir

愛滋病藥物中間體 For AIDS treatment 2015 sales: 8M

產品介紹Product

Pentobarbital Sodium (鎮定安眠用, calmative)

2015 sales:12M

Pent-2

Antidepressant (Duloxetine) 2013年底專利到期 Patent expired in the end of 2013 2014 sales: 12 M 2015 sales: 3M

Antidepressant (S-MMAA) Duloxetine之中間體 intermediate of Duloxetine 2014 sales: 27 M 2015 sales: 22 M

  • Hydroxychloroquine sulfate

  • 2015sales: 112M

風濕性關節炎藥物 For rheumatoid arthritis 4個客戶 4 customers

GMP Status(GMP現況)

API CGMP
certified
CEP
(EDQM)
DMF
(USA)
MF
(Japan)
DMF
(Canada)
(TFDA)
Valproic
Acid
(*)
2003 2004 2003 2008 2008
Allopurinol 2004 2003 2011
Probucol 2004 2004
Sodium
Valproate
2004 2006
Divalproex
Sodium
(**)
2005 2005 2010
Bisoprolol
Fumarate
2006
Pentobarbital
Sodium
2009 2
011
Propafenone
Hydrochloride
2010 2012 2010 2012 2012
Methylphenidate
HCl
2
011
2014
Duloxetine
Hydrochloride
2012 2014 2010/2011
Thiopental
acid
2012
Loxoprofen
Sodium
Hydrate
2012 2011
Articaine
Hydrochloride
2013 2014
Hydroxychloroquine
Sulfate
2014 2014
Clindamycin
Palmitate
HCl
2011
Cyclophosphamide 2012

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010

敬 請 指 教